摘要
目的探讨慢性髓性白血病(CML)慢性期衍生9号染色体ASS基因缺失与非缺失患者的临床特征及疗效。方法分析初始治疗方案为伊马替尼并采用BCR/ABL1/ASS13色融合探针检测ASS基因是否缺失的CML患者的临床资料,分为缺失组(n=27)和非缺失组(n=92),分析其临床特征、治疗效果及预后。结果119例患者平均年龄37.22±12.72岁,缺失组和非缺失组患者的sokal评分差异有统计学意义(χ^(2)=4.304,P=0.038),其他一般特征差异无统计学意义(P>0.05)。缺失组的3个月完全细胞遗传学反应(CCyR)率及6个月CCyR率、BCR-ABL^(IS)≤1%率均低于非缺失组(均P<0.05)。随访中位数为35.0(3.0~60.0)个月,缺失组PFS低于非缺失组(χ^(2)=4.293,P=0.038),两组OS比较差异无统计学意义(χ^(2)=0.008,P=0.931)。结论伊马替尼治疗的CML慢性期患者中ASS基因缺失导致治疗疗效不佳及预后不良,且更易出现疾病进展。
Objective To investigate the clinical characteristics of patients with chronic myeloid leukemia(CML)in chronic phase with deletion and non-deletion of the argininosuccinate synthesis gene(ASS gene)on the derivative chromosome 9.Methods The clinical data of patients with CML initially treated with imatinib and BCR/ABL1/ASS13-color fusion probe to detect ASS gene deletion were analyzed.The patients were divided into deletion group(n=27)and non-deletion group(n=92).Clinical characteristics,treatment effects,and prognosis were analyzed.Results The average age of 119 patients was 37.22±12.72 years old.The sokal score differed between the deletion and non-deletion groups(χ^(2)=4.304,P=0.038).No statistically significant difference in other general characteristics was found(P>0.05).The 3-month CCyR rate,6-month CCyR rate,and BCR-ABL^(IS)≤1%rate in the deletion group were lower than those in the non-deletion group(P<0.05).The median follow-up of 119 patients was 35.0(3.0-60.0)months.The PFS in the deletion group was lower than that in the non-deletion group(χ^(2)=4.293,P=0.038).Overall survival was not significantly different between the two groups(χ^(2)=0.008,P=0.931).Conclusion The deletion of the ASS gene in patients with chronic CML is related to the poor efficacy of imatinib treatment,poor prognosis,and high risk of disease progression.
作者
高冠论
周璇
许娜
刘晓力
魏婷
李庆山
GAO Guanlun;ZHOU Xuan;XU Na;LIU Xiaoli;WEI Ting;LI Qingshan(Department of Hematology,Guangzhou Red Cross Hospital(The Affiliated Hospital,Jinan University),Guangzhou 510220,China;Department of Hematology,Nanfang Hospital of Southern Medical University,Guangzhou 510515,China)
出处
《肿瘤防治研究》
CAS
2023年第3期283-287,共5页
Cancer Research on Prevention and Treatment
基金
广东省自然科学基金(2214050003863)
广州市卫生健康科技项目(20221A010013)
广州市红十字会医院院内课题资助项目(2016-43)。